Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FK949E switching study in bipolar depression
NCT02362412Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Feb 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of quetiapine in bipolar disorder (BD), sponsored by Astellas Pharma. Primary endpoint: Montgomery-Asberg Depression Rating Scale at 20 weeks. Started Feb 2015; status: completed.
02
Drugs
quetiapine
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT02362412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02362412.